Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [1] ACUTE PHARMACOLOGICAL CONVERSION OF ATRIAL-FIBRILLATION AND FLUTTER - THE ROLE OF FLECAINIDE, PROPAFENONE, AND VERAPAMIL
    KINGMA, JH
    SUTTORP, MJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (05): : A56 - A61
  • [2] Pharmacological treatment of atrial fibrillation
    Davy, JM
    Razcka, F
    Beck, L
    Cung, TT
    Combes, N
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2004, 97 : 63 - 70
  • [3] Pharmacological treatment of atrial fibrillation
    Leenhardt, A
    Thomas, O
    Coumel, P
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1997, 90 : 41 - 46
  • [4] Pharmacological Treatment for Atrial Fibrillation
    Sugi, Kaoru
    Noro, Mahito
    Sakata, Takao
    Tezuka, Naoki
    Nakae, Takeshi
    Kumagai, Kenta
    Sakai, Tsuyoshi
    Numata, Ayaka
    Itakura, Hidetoshi
    Moriyama, Akiyoshi
    Kujime, Shingo
    JOURNAL OF ARRHYTHMIA, 2005, 21 (03) : 358 - 370
  • [5] PROPAFENONE FOR CHRONIC TREATMENT OF PAROXYSMAL ATRIAL-FIBRILLATION
    HAMMILL, S
    WOOD, D
    SUGRUE, D
    GERSH, B
    OSBORN, M
    HOLMES, D
    CIRCULATION, 1985, 72 (04) : 171 - 171
  • [6] PHARMACOLOGICAL CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION: A RANDOMIZED STUDY OF PROPAFENONE AND AMIODARONE
    Taha, H. S.
    Mashaal, M. S.
    Omar, R. M.
    CARDIOLOGY, 2013, 125 : 175 - 175
  • [7] INTRAVENOUS AND ORAL PROPAFENONE IN THE TREATMENT OF PAROXYSMAL ATRIAL-FIBRILLATION
    COINTE, R
    METGE, M
    BRU, P
    VRANCEA, F
    GERARD, R
    PAGANELLI, F
    LEVY, S
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1993, 42 (04): : 223 - 227
  • [8] Comparative dimensional analysis of atrial fibrillation of treatment of PPF (propafenone)
    Tien, Kuang-Fu
    ICNC 2007: Third International Conference on Natural Computation, Vol 2, Proceedings, 2007, : 460 - 461
  • [9] Pharmacological approaches in the treatment of atrial fibrillation
    Tamargo, J
    Caballero, R
    Deplón, E
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (01) : 13 - 28
  • [10] THE PHARMACOLOGICAL TREATMENT OF ATRIAL-FIBRILLATION
    BOLOGNESI, R
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 (03) : 617 - 628